These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 27367551

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Progress in the treatment of bleeding disorders.
    Bergman GE.
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [Abstract] [Full Text] [Related]

  • 5. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
    Franchini M, Makris M, Santagostino E, Coppola A, Mannucci PM.
    Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
    [Abstract] [Full Text] [Related]

  • 6. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
    Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, Grigorian A, Ewenstein B, Wong WY.
    Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
    [Abstract] [Full Text] [Related]

  • 7. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD, Holle LA, Wolberg AS.
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [Abstract] [Full Text] [Related]

  • 8. Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
    Fukutake K.
    Semin Thromb Hemost; 2000 Jan; 26(1):29-32. PubMed ID: 10805278
    [Abstract] [Full Text] [Related]

  • 9. Hemophilia in Iran.
    Dorgalaleh A, Dadashizadeh G, Bamedi T.
    Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
    [Abstract] [Full Text] [Related]

  • 10. Joint WFH-ISTH session: issues in clinical trial design.
    Peyvandi F, Farrugia A, Iorio A, Key NS, Srivastava A.
    Haemophilia; 2014 May; 20 Suppl 4():137-44. PubMed ID: 24762289
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J, Chojnowski K, Klukowska A, Łetowska M, Mital A, Podolak-Dawidziak M, Windyga J, Zawilska K, Working Group on Hemostasis of the Polish Society of Hematologists and Transfusiologists.
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [Abstract] [Full Text] [Related]

  • 12. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.
    Johannessen M, Andreasen RB, Nordfang O.
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):239-42. PubMed ID: 10870803
    [Abstract] [Full Text] [Related]

  • 13. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M.
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [Abstract] [Full Text] [Related]

  • 14. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A.
    Duan X, Tang M, Zhang J, Yu H, Xu R.
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429
    [Abstract] [Full Text] [Related]

  • 15. The use of continuous infusion of factor concentrates in the treatment of hemophilia.
    Bona RD, Weinstein RA, Weisman SJ, Bartolomeo A, Rickles FR.
    Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914
    [Abstract] [Full Text] [Related]

  • 16. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
    Berntorp E, Shapiro AD, Waters J, Astermark J.
    Haemophilia; 2014 Sep; 20(5):e362-4. PubMed ID: 25156443
    [No Abstract] [Full Text] [Related]

  • 17. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
    Iorio A, Matino D, D'Amico R, Makris M.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD004449. PubMed ID: 20687076
    [Abstract] [Full Text] [Related]

  • 18. Safety of the new generation recombinant factor concentrates.
    Schlesinger KW, Ragni MV.
    Expert Opin Drug Saf; 2002 Sep 04; 1(3):213-23. PubMed ID: 12904137
    [Abstract] [Full Text] [Related]

  • 19. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G, Spranger T, Brackmann HH.
    Haematologica; 2003 Jun 04; 88(6):EREP05. PubMed ID: 12826531
    [Abstract] [Full Text] [Related]

  • 20. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M, Coppola A, Tagliaferri A, Lippi G.
    Semin Thromb Hemost; 2013 Oct 04; 39(7):772-8. PubMed ID: 24014071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.